Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million
Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee.
RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints.
Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 million upon signature, and further milestone payments of $ 70 million prior to regulatory approval. The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX to Shionogi will be carried out exclusively by Grünenthal.
“RTX is a promising asset for more than 300 million patients worldwide who suffer from osteoarthritis and seek a meaningful non-opioid therapy option”,says Gabriel Baertschi, Chief Executive Officer, Grünenthal. “With their established presence, strong commercial capabilities and wealth of experience in the pain market, Shionogi is our partner of choice to successfully bring RTX to patients in Japan.”
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist with a well-validated mechanism of action. An ongoing clinical Phase III programme across sites in Europe, the US, Latin America, South Africa and Japan aims to enable marketing approval for the investigational medicine. New drug applications, including Japan, are targeted for 2024, leading to a potential market entry of RTX in 2025. If the outcome of the Phase III programme is positive, Grünenthal intends to explore the potential of RTX for the treatment of osteoarthritis-related pain in other joints beyond the knee. The global osteoarthritis market is expected to grow to approximately $ 11.0 billion in 2025. Japan represents one of the most important markets in Asia, with significant revenue potential for RTX.
RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis. Resiniferatoxin is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This may result in long-lasting pain relief. Initial data shows a long-lasting and significant analgesic effect and functional improvements compared to placebo, as well as a favourable safety profile.
 Cieza, A., Causey, K., Kamenov, K., Hanson, S. W., Chatterji, S., & Vos, T. (2020). Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10267), 2006-2017.
 MarketsAndMarkets Report; Osteoarthritis Therapeutics Market by Anatomy (Knee, Hand), Drug Type (NSAIDs, Analgesics, Corticosteroids), Route of Administration (Parenteral), Distribution Channel (Hospital Pharmacies),Purchasing Pattern (Prescription Drugs) - Global Forecast to 2025; 2020. https://www.marketsandmarkets.com/Market-Reports/osteoarthritis-therapeutics-market-209565994.html
 ICD-11 https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f558562409
 National Institute of Arthritis and Musculoskeletal and Skin Diseases; What Causes Osteoarthritis, Symptoms & More | NIAMS (nih.gov)
Osteoarthritis (OA) can be defined as a group of distinct but overlapping diseases. They may have different etiologies but similar biological, morphological, and clinical outcomes that affect the articular cartilage, subchondral bone, ligaments, joint capsule, synovial membrane, and periarticular muscles. OA is the most common joint disease in people aged 65 and over. Its etiology is not fully understood, although several related factors include female gender, genetics, metabolism, and excessive mechanical stress. The diagnosis of OA is primarily based on the clinical history and physical examination. The cardinal radiographic features of OA are focal/non-uniform narrowing of the joint space in the areas subjected to the most pressure, subchondral cysts, subchondral sclerosis, and osteophytes.
Osteoarthritis is a joint disease in which the tissues in the joint break down over time. Common symptoms of osteoarthritis include joint pain, stiffness and swelling, as well as changes in how the joint moves and feeling like the joint is loose or unstable. The most commonly affected joints include the knees, hips, hands, neck and lower back. Treatment of osteoarthritis usually includes exercises, maintaining a healthy weight, wearing braces to help with stability, and taking medication, if prescribed. Many patients will ultimately require joint replacement surgery.
Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company based in Japan, dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” We have declared that it will focus on psychoneurological diseases and pain as priority diseases as well as infectious diseases and contributed to improving the activities of daily living and quality of life and productivity of people suffering from pain. For more information, please visit https://www.shionogi.com/global/en/contact.html
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.
More information: www.grunenthal.com
Click here for our Grünenthal Report 2021/2022
Follow us on:
LinkedIn: Grunenthal Group
For further information please contact
Head Global Communication
Phone: +49 241 569-2555
Communication Business Partner
Phone: +49 241 569-1428
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
An ordeal that ends on a plate in a tourist resort: Live transports of calves to the Canary Islands9.8.2022 16:47:11 CEST | Press release
Every week, cattle are shipped to the Canary Islands under unacceptable conditions. These transports are extremely long. The animals stand on the truck for even more than 100 hours non-stop. Now, in summer, sweltering heat must be added as well as poor water supply, no or too little food, bedding of excrements and urine, lack of space, and an acrid ammonia smell. Once on the islands, the animals, only a few months old, await death in the slaughterhouse. A trade that is enhanced by subsidies and slaughter premiums .
COUNTRY QUEEN IS THE FIRST KENYAN LICENSED BRANDED SERIES ON NETFLIX2.8.2022 14:57:38 CEST | Press release
Country Queen, which premiered in 190 countries exclusively on Netflix 15th of July, is the first high-quality drama series from East Africa to reach a global audience! Launching as No. 1 TV Show in Kenya on Netflix for two weeks in a row, the series continues to gain stellar reviews, more traction and global recognition.
Make some noise for endangered species: Krombacher and Wacken Open Air present the "Growling Creatures" – the first metal band consisting of endangered animals1.8.2022 10:48:17 CEST | Press release
Krombach / Germany, August1st 2022. What do grey seals, cuckoos, and lynx have in common? They are all rare, European native species whose survival is threatened, and they are part of the "Growling Creatures" - the first metal band consisting of endangered animals. Presented by Krombacher and the legendary metal festival Wacken Open Air (W:O:A), this summer the Growling Creatures are drawing attention to their threat and are making some noise for endangered species. "With Krombacher, we have long been committed to domestic and international species protection projects," says Peter Lemm, Head of Communications of the Krombacher brewery. "As a new partner of the Wacken Open Air, it was important for us to create an authentic connection between our sustainable commitment and entertainment with a twinkle in the eye. The Growling Creatures represent exactly this - as musical newcomers of the year, they deliver the best metal sound for the good cause." Animalistic Metal Sound On their mini-E
R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories19.7.2022 08:00:00 CEST | Press release
Darmstadt, July 19, 2022 – As a fully integrated solution, the new and completely automated RIDA®UNITY system combines sample extraction, PCR setup, real-time PCR and result evaluation in a common workflow. The biotechnology company R-Biopharm AG announced today that it has received the CE mark and will begin selling the new, fully automated RIDA®UNITY system for molecular detection of infectious diseases throughout Europe. "With the RIDA®UNITY system, R-Biopharm is purposefully taking the path from a provider of individual solutions to a system provider in the field of molecular diagnostics," stated Christian Dreher, CEO of R-Biopharm. "We are very happy to make this system solution available to all molecular biology laboratories throughout Europe." Unique combination of different tools The RIDA®UNITY system combines the various steps in the analysis of patient samples into an integrated workflow – nucleic acid extraction, PCR setup, subsequent real-time PCR and the evaluation of the
After cake attack on Mona Lisa: Castello CUBE has to be hidden in a safe in the Swiss Alps!14.7.2022 13:30:00 CEST | Press release
Zug, Switzerland - It is the most expensive cube ever made, funded by the booming cryptocurrency Castello Coin. For now, the world-famous Castello CUBE will no longer be open to the public – to protect it from damage and theft. The Castello CUBE attracted worldwide attention when the golden cube by artist Niclas Castello was shown first in New York's Central Park and at the Venice Biennale this year. The work of art, unique in the world, was made of 24 carats, 999.9 fine gold in the oldest art foundry in Europe and weighs 410 lbs. The material value alone is $11.7 Million US-Dollars. Coin and CUBE each act as a bridge between the classic financial world, the world of traditional forms of investment and traditional art and the new world – the world of cryptocurrencies and the digital age. Initially, the Cube was supposed to be shown in other locations in the US, Europe, Asia and the United Arab Emirates and inspire people worldwide. But security experts advise against it after a risk an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom